IMUX
Immunic, Inc.
Price Chart
Latest Quote
$14.84
+0.13 (+0.88%)
Current Price
| Previous Close | $14.71 |
| Open | $14.81 |
| Day High | $15.11 |
| Day Low | $14.45 |
| Volume | 24,895 |
Stock Information
| Shares Outstanding | 13.62M |
| Total Debt | $421K |
| Cash Equivalents | $186.63M |
| Net Income | $-104.29M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $202.14M |
| EPS (TTM) | $-4.77 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $14.16M |
| Income | $-104.29M |
| Book/sh | $11.10 |
| Cash/sh | $13.70 |
| Employees | 95 |
Financial Ratios
| Quick Ratio | 4.87 |
| Current Ratio | 4.92 |
| Debt/Eq | 0.28 |
Returns & Margins
| ROA | -65.18% |
| ROE | -142.91% |
Ownership
| Insider Ownership | 0.97% |
| Institutional Ownership | 46.89% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.18 |
| P/B | 1.34 |
Analyst Data
| Recommendation | none |
| Target Price | $44.67 |
Technical Indicators
| SMA20 | $13.98 |
| SMA50 | $12.22 |
| SMA200 | $9.36 |
| RSI | 52.71 |
| ATR | 1.1687 |
| Shares Float | 11.84M |
| Short Float | 13.71% |
| Short Ratio | 6.14 |
| Volatility | 1.39 |
| Rel Volume | 0.11 |
Performance History
| Week | +4.51% |
| Month | +14.42% |
| Quarter | +12.42% |
| 6 Months | +146.10% |
| YTD | +154.55% |
| Year | +109.60% |
| 3 Years | -11.14% |
| 5 Years | -88.85% |
| 10 Years | -99.41% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $14.84 | 24,895 |
| 2026-06-24 | $14.71 | 225,600 |
| 2026-06-23 | $15.07 | 224,300 |
| 2026-06-22 | $14.75 | 302,300 |
| 2026-06-18 | $14.20 | 263,700 |
| 2026-06-17 | $14.20 | 129,600 |
| 2026-06-16 | $13.71 | 118,900 |
| 2026-06-15 | $14.01 | 138,900 |
| 2026-06-12 | $13.86 | 195,600 |
| 2026-06-11 | $13.07 | 360,800 |
| 2026-06-10 | $11.71 | 190,300 |
| 2026-06-09 | $12.26 | 254,600 |
| 2026-06-08 | $12.06 | 201,700 |
| 2026-06-05 | $12.77 | 261,400 |
| 2026-06-04 | $14.43 | 207,300 |
| 2026-06-03 | $14.17 | 252,000 |
| 2026-06-02 | $14.64 | 248,400 |
| 2026-06-01 | $15.13 | 171,500 |
| 2026-05-29 | $14.96 | 366,100 |
| 2026-05-28 | $14.97 | 378,300 |
| 2026-05-27 | $14.00 | 395,400 |
| 2026-05-26 | $12.97 | 247,900 |
About Immunic, Inc.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
đ° Latest News
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
Proactive âĸ 2026-05-28T14:29:00Z
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
Proactive âĸ 2026-05-27T13:06:00Z
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
Benzinga âĸ 2026-05-27T10:17:45Z
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
Proactive âĸ 2026-05-19T13:33:00Z
Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?
Simply Wall St. âĸ 2026-05-17T14:31:41Z
Immunic advances Phase 3 MS program, eyes topline data by year-end
Proactive âĸ 2026-05-13T13:04:00Z
Immunic CEO on Q1 highlights, new appointments and upcoming milestones
Proactive âĸ 2026-05-07T12:47:24Z
Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout
Proactive âĸ 2026-04-28T12:40:00Z
Immunic to implement 1-for-10 reverse stock split
Proactive âĸ 2026-04-23T12:52:00Z
Immunic COO highlights the importance of science-led innovation to mark World Health Day
Proactive âĸ 2026-04-07T12:05:53Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $103,228,000 | $98,052,000 | $99,223,000 | $86,518,000 |
| Other Income Expense | $5,016,000 | $-5,845,000 | $2,536,000 | $-34,930,000 |
| Other Non Operating Income Expenses | $5,016,000 | $-5,845,000 | $2,536,000 | $-1,960,000 |
| Net Non Operating Interest Income Expense | $1,040,000 | $3,390,000 | $3,075,000 | $1,041,000 |
| Operating Expense | $103,228,000 | $98,052,000 | $99,223,000 | $86,518,000 |
| General And Administrative Expense | $21,245,000 | $18,006,000 | $16,008,000 | $15,263,000 |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-97,172,000 | $-100,507,000 | $-93,612,000 | $-120,407,000 |
| Net Interest Income | $1,040,000 | $3,390,000 | $3,075,000 | $1,041,000 |
| Interest Income | $1,040,000 | $3,390,000 | $3,075,000 | $1,041,000 |
| Normalized Income | $-97,172,000 | $-100,507,000 | $-93,612,000 | $-87,437,000 |
| Net Income From Continuing And Discontinued Operation | $-97,172,000 | $-100,507,000 | $-93,612,000 | $-120,407,000 |
| Total Operating Income As Reported | $-103,228,000 | $-98,052,000 | $-99,223,000 | $-119,488,000 |
| Net Income Common Stockholders | $-97,172,000 | $-100,507,000 | $-93,612,000 | $-120,407,000 |
| Net Income | $-97,172,000 | $-100,507,000 | $-93,612,000 | $-120,407,000 |
| Net Income Including Noncontrolling Interests | $-97,172,000 | $-100,507,000 | $-93,612,000 | $-120,407,000 |
| Net Income Continuous Operations | $-97,172,000 | $-100,507,000 | $-93,612,000 | $-120,407,000 |
| Pretax Income | $-97,172,000 | $-100,507,000 | $-93,612,000 | $-120,407,000 |
| Interest Income Non Operating | $1,040,000 | $3,390,000 | $3,075,000 | $1,041,000 |
| Operating Income | $-103,228,000 | $-98,052,000 | $-99,223,000 | $-86,518,000 |
| Special Income Charges | - | - | $0 | $-32,970,000 |
| Per Share | ||||
| Diluted EPS | $-6.20 | $-10.00 | $-21.10 | $-37.80 |
| Basic EPS | $-6.20 | $-10.00 | $-21.10 | $-37.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-103,060,000 | $-97,918,000 | $-99,112,000 | $-53,471,000 |
| Reconciled Depreciation | $168,000 | $134,000 | $111,000 | $77,000 |
| EBITDA (Bullshit earnings) | $-103,060,000 | $-97,918,000 | $-99,112,000 | $-86,441,000 |
| EBIT | $-103,228,000 | $-98,052,000 | $-99,223,000 | $-86,518,000 |
| Diluted Average Shares | $15,568,803 | $10,017,476 | $4,432,005 | $3,181,900 |
| Basic Average Shares | $15,568,803 | $10,017,476 | $4,432,005 | $3,181,900 |
| Diluted NI Availto Com Stockholders | $-97,172,000 | $-100,507,000 | $-93,612,000 | $-120,407,000 |
| Research And Development | $81,983,000 | $80,046,000 | $83,215,000 | $71,255,000 |
| Selling General And Administration | $21,245,000 | $18,006,000 | $16,008,000 | $15,263,000 |
| Other Gand A | $21,245,000 | $18,006,000 | $16,008,000 | $15,263,000 |
| Total Unusual Items | - | $-4,796,000 | $0 | $-32,970,000 |
| Total Unusual Items Excluding Goodwill | - | $-4,796,000 | $0 | $-32,970,000 |
| Gain On Sale Of Security | - | $-4,796,000 | - | - |
| Impairment Of Capital Assets | - | - | $0 | $32,970,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-6,673,000 | $18,429,000 | $28,931,000 | $113,684,000 |
| Total Assets | $24,052,000 | $40,868,000 | $54,299,000 | $127,753,000 |
| Total Non Current Assets | $1,183,000 | $1,536,000 | $1,765,000 | $1,889,000 |
| Current Assets | $22,869,000 | $39,332,000 | $52,534,000 | $125,864,000 |
| Other Current Assets | $1,200,000 | $1,109,000 | $1,069,000 | $1,225,000 |
| Prepaid Assets | $2,064,000 | $1,871,000 | $2,314,000 | $5,608,000 |
| Receivables | $4,122,000 | $684,000 | $2,477,000 | $2,657,000 |
| Other Receivables | $3,789,000 | - | $1,104,000 | - |
| Taxes Receivable | $333,000 | $684,000 | $1,373,000 | $2,657,000 |
| Cash Cash Equivalents And Short Term Investments | $15,483,000 | $35,668,000 | $46,674,000 | $116,374,000 |
| Cash And Cash Equivalents | $15,483,000 | $35,668,000 | $46,674,000 | $106,745,000 |
| Other Non Current Assets | - | - | - | $43,000 |
| Goodwill And Other Intangible Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | $577,000 | $1,004,000 | $1,334,000 | $1,563,000 |
| Long Term Debt And Capital Lease Obligation | $107,000 | $264,000 | $639,000 | $992,000 |
| Current Debt And Capital Lease Obligation | $470,000 | $740,000 | $695,000 | $571,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $30,725,000 | $22,439,000 | $25,368,000 | $14,069,000 |
| Total Non Current Liabilities Net Minority Interest | $107,000 | $264,000 | $639,000 | $992,000 |
| Current Liabilities | $30,618,000 | $22,175,000 | $24,729,000 | $13,077,000 |
| Other Current Liabilities | $1,365,000 | $676,000 | $271,000 | $239,000 |
| Payables And Accrued Expenses | $26,615,000 | $20,405,000 | $22,303,000 | $11,377,000 |
| Payables | $10,138,000 | $7,846,000 | $5,099,000 | $4,281,000 |
| Other Payable | $645,000 | $285,000 | $373,000 | $532,000 |
| Accounts Payable | $9,493,000 | $7,561,000 | $4,726,000 | $3,749,000 |
| Equity | ||||
| Common Stock Equity | $-6,673,000 | $18,429,000 | $28,931,000 | $113,684,000 |
| Total Equity Gross Minority Interest | $-6,673,000 | $18,429,000 | $28,931,000 | $113,684,000 |
| Stockholders Equity | $-6,673,000 | $18,429,000 | $28,931,000 | $113,684,000 |
| Gains Losses Not Affecting Retained Earnings | $2,648,000 | $4,209,000 | $3,759,000 | $3,035,000 |
| Other Equity Adjustments | $2,648,000 | $4,209,000 | $3,759,000 | $3,035,000 |
| Retained Earnings | $-608,571,000 | $-511,399,000 | $-410,892,000 | $-317,280,000 |
| Other | ||||
| Ordinary Shares Number | $12,038,262 | $9,015,086 | $4,517,773 | $3,930,728 |
| Share Issued | $12,038,262 | $9,015,086 | $4,517,773 | $3,930,728 |
| Tangible Book Value | $-6,673,000 | $18,429,000 | $28,931,000 | $113,684,000 |
| Invested Capital | $-6,673,000 | $18,429,000 | $28,931,000 | $113,684,000 |
| Working Capital | $-7,749,000 | $17,157,000 | $27,805,000 | $112,787,000 |
| Capital Lease Obligations | $577,000 | $1,004,000 | $1,334,000 | $1,563,000 |
| Total Capitalization | $-6,673,000 | $18,429,000 | $28,931,000 | $113,684,000 |
| Additional Paid In Capital | $599,241,000 | $525,611,000 | $436,060,000 | $427,925,000 |
| Capital Stock | $9,000 | $8,000 | $4,000 | $4,000 |
| Common Stock | $9,000 | $8,000 | $4,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $107,000 | $264,000 | $639,000 | $992,000 |
| Current Capital Lease Obligation | $470,000 | $740,000 | $695,000 | $571,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,168,000 | $354,000 | $1,460,000 | $890,000 |
| Current Accrued Expenses | $16,477,000 | $12,559,000 | $17,204,000 | $7,096,000 |
| Net PPE | $1,183,000 | $1,536,000 | $1,765,000 | $1,846,000 |
| Gross PPE | $1,183,000 | $1,536,000 | $1,765,000 | $1,846,000 |
| Other Properties | $1,183,000 | $1,536,000 | $1,765,000 | $1,846,000 |
| Treasury Shares Number | - | - | $0 | - |
| Other Short Term Investments | - | - | $0 | $9,629,000 |
| Goodwill | - | - | - | $0 |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-85,967,000 | $-85,030,000 | $-71,162,000 | $-65,256,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-85,806,000 | $-84,766,000 | $-70,828,000 | $-65,144,000 |
| Cash Flow From Continuing Operating Activities | $-85,806,000 | $-84,766,000 | $-70,828,000 | $-65,144,000 |
| Operating Gains Losses | - | $30,000 | $523,000 | $4,757,000 |
| Investing Activities | ||||
| Capital Expenditure | $-161,000 | $-264,000 | $-334,000 | $-112,000 |
| Investing Cash Flow | $-161,000 | $-264,000 | $9,462,000 | $-9,741,000 |
| Cash Flow From Continuing Investing Activities | $-161,000 | $-264,000 | $9,462,000 | $-9,741,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $65,395,000 | $191,000 | $853,000 | $95,573,000 |
| Financing Cash Flow | $65,577,000 | $74,541,000 | $1,033,000 | $95,760,000 |
| Cash Flow From Continuing Financing Activities | $65,577,000 | $74,541,000 | $1,033,000 | $95,760,000 |
| Net Common Stock Issuance | $65,395,000 | $191,000 | $853,000 | $39,584,000 |
| Common Stock Issuance | $65,395,000 | $191,000 | $853,000 | $39,584,000 |
| Net Other Financing Charges | - | $74,273,000 | - | - |
| Net Preferred Stock Issuance | - | - | $0 | $55,989,000 |
| Preferred Stock Issuance | - | - | $0 | $55,989,000 |
| Other | ||||
| End Cash Position | $15,483,000 | $35,668,000 | $46,674,000 | $106,745,000 |
| Beginning Cash Position | $35,668,000 | $46,674,000 | $106,745,000 | $86,863,000 |
| Effect Of Exchange Rate Changes | $205,000 | $-517,000 | $262,000 | $-993,000 |
| Changes In Cash | $-20,390,000 | $-10,489,000 | $-60,333,000 | $20,875,000 |
| Proceeds From Stock Option Exercised | $182,000 | $77,000 | $180,000 | $187,000 |
| Net PPE Purchase And Sale | $-161,000 | $-264,000 | $-334,000 | $-112,000 |
| Purchase Of PPE | $-161,000 | $-264,000 | $-334,000 | $-112,000 |
| Change In Working Capital | $1,838,000 | $330,000 | $15,048,000 | $9,530,000 |
| Change In Other Current Liabilities | $-715,000 | $159,000 | $96,000 | $-124,000 |
| Change In Other Current Assets | $-3,161,000 | $1,886,000 | $3,858,000 | - |
| Change In Payables And Accrued Expense | $5,714,000 | $-1,715,000 | $11,094,000 | $2,161,000 |
| Change In Accrued Expense | $4,477,000 | $-4,860,000 | $10,277,000 | $1,362,000 |
| Change In Payable | $1,237,000 | $3,145,000 | $817,000 | $799,000 |
| Change In Account Payable | $1,237,000 | $3,145,000 | $817,000 | $799,000 |
| Other Non Cash Items | $497,000 | $6,720,000 | - | - |
| Stock Based Compensation | $8,863,000 | $8,527,000 | $7,102,000 | $7,929,000 |
| Depreciation Amortization Depletion | $168,000 | $134,000 | $111,000 | $77,000 |
| Depreciation And Amortization | $168,000 | $134,000 | $111,000 | $77,000 |
| Net Foreign Currency Exchange Gain Loss | $0 | $30,000 | $523,000 | $4,757,000 |
| Net Income From Continuing Operations | $-97,172,000 | $-100,507,000 | $-93,612,000 | $-120,407,000 |
| Net Investment Purchase And Sale | - | $0 | $9,796,000 | $-9,629,000 |
| Sale Of Investment | - | $0 | $9,796,000 | - |
| Change In Prepaid Assets | - | - | $3,858,000 | $7,493,000 |
| Asset Impairment Charge | - | - | $0 | $32,970,000 |
| Purchase Of Investment | - | - | - | $-9,629,000 |
Fetched: 2026-06-25